CYCLACEL PHARMACEUTICALS ($CYCC) is expected to release its quarterly earnings data on Monday, March 17th after market close, per Finnhub. Analysts are expecting revenue of $10,200 and earnings of -$0.30 per share.
You can see Quiver Quantitative's $CYCC stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
CYCLACEL PHARMACEUTICALS Hedge Fund Activity
We have seen 8 institutional investors add shares of CYCLACEL PHARMACEUTICALS stock to their portfolio, and 4 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ARMISTICE CAPITAL, LLC added 435,461 shares (+300.3%) to their portfolio in Q4 2024, for an estimated $163,733
- UBS GROUP AG added 34,764 shares (+276.9%) to their portfolio in Q4 2024, for an estimated $13,071
- TWO SIGMA SECURITIES, LLC added 28,580 shares (+inf%) to their portfolio in Q4 2024, for an estimated $10,746
- CITADEL ADVISORS LLC removed 12,255 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $12,132
- HRT FINANCIAL LP removed 10,694 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $10,587
- TOWER RESEARCH CAPITAL LLC (TRC) added 1,583 shares (+39.5%) to their portfolio in Q4 2024, for an estimated $595
- GEODE CAPITAL MANAGEMENT, LLC added 219 shares (+2.1%) to their portfolio in Q4 2024, for an estimated $82
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
